Table 2.

Cumulative incidence (%) and 95% CIs for long-term adverse health outcomes (cumulative incidence at 15 yrs from diagnosis, %): overall and by tumor location at presentation

	Overall (n = 240)	Posterior fossa, PA, GTR (n = 51)	Hypothalamic/chiasmatic, no progression (n = 35)	Hypothalamic/chiasmatic with progression (n = 41)	Cerebral hemisphere (n = 38)	Brainstem (n = 32)
Visual acuity
Legal blindness (R or L)	17.5 (10.4–24.6)	0.0	27.1 (11.3–42.9)	56.9 (33.3–100.0)	5.3 (0.0–12.5)	5.1 (0.0–15.0)
Field deficit (R or L)	31.5 (22.7–40.3)	5.9 (0.0–14.5)	NAR	47.5 (24.1–100.0)	58.6 (21.7–95.5)	11.3 (0.0–24.0)
Endocrine
Obesity/overweight	53.2 (42.8–63.6)	25.7 (12.7–38.7)	NAR	75.0 (57.6–100.0)	41.6 (17.8–65.4)	45.4 (24.3–66.5)
Growth hormone deficiency	29.0 (22.2–35.8)	0.0	57.9 (39.9–75.9)	62.3 (45.4–100.0)	6.6 (0.0–15.7)	25.9 (8.0–43.7)
Hypothyroid	32.7 (24.6–40.8)	3.9 (0.0–11.5)	NAR	67.9 (49.1–100.0)	22.7 (7.0–38.4)	16.0 (2.9–29.1)
ACTH deficiency	25.7 (18.9–32.5)	2.0 (0.0–5.8)	NAR	55.6 (37.9–100.0)	9.7 (0.0–20.6)	18.8 (2.7–35.0)
Hyperinsulinism/insulin resistant	24.0 (13.2–34.7)	7.7 (0.0–18.3)	56.8 (6.5–100.0)	23.8 (5.5–69.9)	6.8 (0.0–16.1)	27.9 (0.0–59.6)
Hearing
Any abnormality (R or L)	21.8 (13.2–30.3)	24.2 (0.0–51.6)	3.3 (0.0–9.8)	20.3 (7.5–74.0)	3.9 (0.0–11.5)	38.2 (16.5–59.8)
Neurologic
Seizure	38.0 (29.5–46.5)	6.0 (0.0–12.7)	26.5 (0.0–53.5)	49.9 (30.6–100.0)	76.3 (59.2–93.4)	27.2 (10.6–43.9)
Chronic headache	40.9 (31.7–50.1)	55.4 (29.1–81.6)	50.8 (27.2–74.5)	23.2 (7.7–77.6)	43.6 (19.4–67.8)	37.3 (15.0–59.7)
Cranial nerve deficit	23.7 (16.7–30.8)	20.7 (7.8–33.5)	24.2 (0.0–51.6)	19.5 (3.6–56.7)	10.5 (0.6–20.4)	52.6 (32.9–72.3)

PA, pilocytic astrocytoma; GTR, gross total resection; NAR, No patients remain at risk at 15 years from diagnosis; ACTH, adrenocorticotropic hormone.